Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA responds to Science Board’s BPA review

This article was originally published in The Tan Sheet

Executive Summary

The agency is formulating a response to its Science Board's review of FDA's draft assessment of bisphenol A's safety in food contact applications. Associate Commissioner for Science Norris Alderson initially replied to the board in a December 2008 letter, agreeing that FDA should focus on BPA applications that might impact infants, including formula packaging (1"The Tan Sheet" Jan. 5, 2009, In Brief). According to a Feb. 9 release, FDA and Health Canada officials held a forum Jan. 30 with manufacturers from both countries to discuss ongoing BPA reduction efforts. FDA says an international regulatory consensus holds that BPA exposure through food packages does not pose a risk to the general population, but the agency continues to review research on the potential low-dose effects of BPA

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel